utsouthwestern.edu
Feb 4, 2025, 16:58
A retrospective study in EGFR+ NSCLC with brain metastases – Clinical Lung Cancer
Clinical Lung Cancer shared a post on X about a recent paper by Wesley Wong et al. published in Clinical Lung Cancer:
“A retrospective study in EGFR+ NSCLC with brain metastases shows that continuing osimertinib and chemo after progression reduces CNS progression vs. chemo alone.
CNS-PFS was longer (9.0 vs. 5.7 months), and salvage brain RT rates were lower (15% vs. 24%).”
Authors: Wesley Wong, Kevin Mok, Giselle Tsui, Tony Mok, Molly Li et al.
More posts featuring Clinical Lung Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32